Single-dose cathepsin L CRISPR nanotherapy mitigates PASC-like lung damage in hamsters
{{output}}
Respiratory post-acute sequelae of COVID-19 (PASC) persists in many SARS-CoV-2 survivors, yet no therapies specifically address its long-term pulmonary damage. We demonstrate that a single-dose CRISPR-CasRx nanotherapy targeting the host enzyme cathepsin L (SC... ...
